Regen生物药厂文件范式变换RNA/DNA基础治癌方法专利

公司组合现有NR2F6和SurvivinGene静默发现

南迭戈市,九月2022年19PR新闻线/-里根生物药厂公司OCC PINK:RGBP)和OCC PINK:RGBP发布 今天向USPTO提交临时专利申请应用覆盖新事物组成,可起常规检查站抑制药作用,同时静默管理T细胞和癌症细胞的基因,如NR2F6和Survi

Aptamers are short DNA or RNA sequences which can function as antibodies – they recognize specific proteins and bind to them.  This new technology takes advantage of the fact that the Company can put its proprietary RNA or DNA sequences which code for inhibitory RNAs on one end of an aptamer while using the other end of the aptamer to bind to, and thus inhibit, a traditional immune checkpoint such as PD-1.  Once the aptamer is internalized into the cell, the proprietary DNA or RNA sequence is converted to an inhibitory RNA which targets other genes involved in T cell function or cancer growth leading to a two-pronged approach to T cell activation or cancer-killing.

数年来我们公司一直在研究RNA治疗方法,survivinRNA疫苗专利以及NR2F6基因静默大卫库斯首席执行官兼公司总裁并发平台技术后, 开发出多项强效治疗候选者

关于Regen生物药厂
Regen生物药厂公开交易生物技术公司(PINK:RGBP)和(PINK:RGBPP)公司专注于免疫学和免疫法空间公司通过临床前和阶段I/II临床试验集中快速开发新技术公司目前侧重于mRNA和小分子治疗癌症和自动机失常regen生物药店补充信息见http://www.regenbiopharmainc.com.

免责声明者:新闻公告中可包含前瞻性声明前瞻报表固有风险和不确定性,其中一些无法预测或量化。未来事件和实际结果可能与前瞻声明中列出、设想或基础内容大相径庭。前瞻声明所涉及的风险和不确定性包括但不限于政府监管效果、竞争和其他物质风险

联系信息

Regen生物药厂
大卫R库斯博士
总裁兼首席执行官
+1-619-722-5505
+1-619-330-2328传真

视图原创内容 :https://www.prnewswire.com/news-releases/regen-biopharma-inc-files-patent-on-paradigm-shifting-rnadna-based-approach-to-cancer-immunotherapy-301627344.html

SOURCE生物药厂